Amy Rothberg, clinical professor of internal medicine in the Division of Metabolism, Endocrinology and Diabetes at the University of Michigan, says it also helps improve outcomes in people with type 2 diabetes and cardiorenal (heart and kidney) conditions, similar to semaglutide
Choose Retatrutide If: Maximum weight loss is the primary goal Previous GLP-1 agonists produced significant nausea (GIP component may help) No specific liver health concerns requiring treatment Tolerance for slightly higher GI side effects during titration Response to dual agonists (like tirzepatide) has been positive Choose Survodutide If: Liver health concerns exist (fatty liver, MASH, elevated liver enzymes) Moderate weight loss goals rather than maximum efficacy priority Interest in potential cardiovascular outcome benefits (CVOT data pending) Preference for a compound with FDA Breakthrough Therapy designation Plans to potentially transition to approved medication once available For most people focused primarily on weight loss, Retatrutide presents the stronger option based on available data
This data should be interpreted with a qualified healthcare provider to inform which GLP-1 type or protocol might align with your biological profile
GLP-1 side effects can include the following: Nausea
The combined receptor activation produces measurable outcomes distinct from single or dual-receptor activation alone
Without insurance, these medications can cost over $1,000 per month, making affordability a major factor when considering treatment
